FluidForm, an expert in the field of human tissue for research, repair, and replacement signed an agreement with Ethicon, a member of the Johnson & Johnson Medical Devices Companies, to develop 3D bioprinted applications using FluidForm’s patented FRESH technology. This collaboration leverages FluidForm’s FRESH 3D bioprinting platform to achieve specific tissue characteristics that cannot be manufactured with conventional techniques.
Manufacturing on Demand
“Ethicon is a global leader in surgery”, Mike Graffeo, FluidForm’s CEO said, “and their 3D Printing Center is a leader in the industry when it comes to applications of 3D printing in medicine. We are thrilled by the impact that FRESH printing can have and are excited to collaborate with Ethicon to deliver on these ambitious goals”.
The ability to recreate functional human tissue for research, training and potential replacement has the potential to transform human health. FRESH printing is a technology that has been proven to recreate biology, from structure to function. FluidForm seeks to deliver on the promise of tissue therapies, in order to radically transform human health and longevity.
* This article is reprinted from 3D Printing Media Network. If you are involved in infringement, please contact us to delete it.
Author: Andrea Gambini
Leave A Comment